NEXGEL, INC.

NXGL
About the company

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions.

Country: United StatesPrice: $3.88Market Cap: $2.1M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2892 (Top 93.4%)PASSFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-17

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-17

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 5✗ 30▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/9 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/9 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-57.9%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-29.3% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-2.6M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-125.0%
      ✗Lynch> 15%
      EBIT / Enterprise Value-142.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-142.6%, ROC=-111.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-28.68%
      ✗PiotroskiROA > 0
      ROA Change YoY-29.87% -> -28.68% (delta: +1.20%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-12.53%, ROA=-28.68%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY31.6% -> 39.5%
      ✓PiotroskiImproved YoY
      Pre-Tax Income / Revenue-50.2%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-125.0%
      ✗Dreman> 12%
      Margin of SafetyP/B=7.1x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-63.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/8 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-44.8%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-125.0%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-85.0% (2023) -> -29.3% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 9.1% -> 39.5%, operating margin -85.0% -> -29.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-297.34%; #5788/6340 (top 91.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+16.00%; #2362/3702 (top 63.8%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-124.97%; #4693/5226 (top 89.8%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0707; #3039/5884 (top 51.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/8 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 4✗ 24▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio7.1x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-142.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-142.6%, ROC=-111.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share7.1x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-8.3%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-66.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=7.1x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low2180% of trailing low ($0.18)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-297.34%; #5788/6340 (top 91.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+2.3792; #578/6449 (top 9.0%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share11.92x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+76508.1%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+5.8006; #481/5247 (top 9.2%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-66.29%; #3942/4519 (top 87.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+546.67%; #76/6202 (top 1.2%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-2.6M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-1.4M
      ✗LynchPositive and growing
      Operating Cash Flow$-1.3M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-12.53%, ROA=-28.68%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-66.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-4.4%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/8 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-1.4M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-66.29%; #3942/4519 (top 87.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio0.43
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-90.1%
      ✗Buffett> 10%
      ROIC - WACC-100.1%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-111.0%
      ✗Greenblatt> 25%
      Current Ratio Change YoY2.07 -> 1.47
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.79x -> 1.09x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.43
      ✗Dreman> 1.5
      Return on Invested Capital-52.7%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-50.4%; FY2024: ROIC=-43.6%; FY2025: ROIC=-52.5%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -52.5%)
      ✗SleepROIC > 12% in a majority of years
    • Growth13% pass✓ 3✗ 10▾

      7 of 8 flag NXGL's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 26.5% vs Rev: 3.4%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.38 (2018) -> $-0.38 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/8 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth99.7%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency4/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 9.1% -> 39.5%, operating margin -85.0% -> -29.3%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR76.1%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts13% pass✓ 2✗ 14▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #2892✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1400/2370 (Top 59.1%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage33% pass✓ 6✗ 9▾

      8 of 12 flag NXGL's debt & leverage — Buffett, Lynch, Dreman +5 more

      LT Debt vs Net Current AssetsLT Debt $0.6M vs NCA $1.4M
      ✓GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.13, IC: -98.6x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.64
      ✗Lynch< 0.33
      Cash - Long-term Debt$-0.3M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change6.24% -> 5.62%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.43
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.64
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.64
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-98.6x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.64
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.6377; #2729/4210 (top 64.8%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($2.1M)
    Revenue: $11.4M+31.5% YoY
    Net Income: $3.0M+8.6% YoY

    Financial Snapshot

    Operating Margin-29.3%
    Return on Equity-67.3%
    Debt / Equity0.13
    Current Ratio1.47
    EPS (Diluted)$-0.38
    Shares Retired−6.4% / −41.8% 2y

    Shareholder Return

    Fiscal 2025

    Issued 6.4% of shares last year, 41.8% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-27
    FY 2023
    Sources
    • 10-K · 2024-04-10
    FY 2022
    Sources
    • 10-K · 2023-03-28
    FY 2021
    Sources
    • 10-K · 2022-03-21
    Market Cap$2.1Mcurrent----$11.6Mest.$29.2Mest.$12.6Mest.$7.9Mest.$14.8Mest.
    Revenue$12.1M↑3%$3.7M↑28%$2.6M↓6%$11.4M↑31%$8.7M↑112%$4.1M↑100%$2.0M↑32%$1.6M
    Operating Income-$5.4M↓78%-$2.5M↓294%-$958.0K↓23%-$3.4M↑6%-$3.6M↓2%-$3.5M↓4%-$3.3M↓30%-$2.6M
    Net Income-$6.2M↓112%-$3.6M↓447%-$927.0K↓30%-$3.0M↑9%-$3.3M↓4%-$3.2M↑33%-$4.7M↓10%-$4.3M
    EPS (Diluted)--$-0.40↓344%$-0.11↓22%$-0.38↑24%$-0.50↑11%$-0.56↑34%$-0.85↑41%$-1.45
    Gross Margin35.1%↓9%30.1%↓31%40.0%↓5%39.5%↑25%31.6%↑246%9.1%↓27%12.5%↑2323%0.5%
    Operating Margin-44.8%↓72%-68.0%↓208%-36.2%↓31%-29.3%↑28%-40.9%↑52%-85.0%↑48%-163.5%↑1%-165.7%
    ROE-125.0%↓100%——-67.3%↓18%-57.0%↑15%-67.2%↓8%-62.1%↓74%-35.7%
    Total Debt$3.2M↑395%$3.2M↑395%$563.0K↓15%$588.0K↓14%$685.0K↓10%$758.0K↑168%$283.0K↓88%$2.3M
    Shareholders' Equity$4.9M↑6%$4.9M↑6%$4.0M↓23%$4.5M↓23%$5.8M↑23%$4.7M↓38%$7.6M↓37%$12.1M
    Current Ratio0.43↓75%0.43↓75%1.70↓10%1.47↓29%2.07↑4%1.98↓77%8.74↑81%4.82
    Debt / Equity0.64↑367%0.64↑367%0.14↑11%0.13↑11%0.12↓26%0.16↑335%0.04↓81%0.19
    Operating Cash Flow-$3.2M↓11%-$2.2M↓440%-$504.0K↓26%-$1.3M↑66%-$3.9M↓19%-$3.2M↓8%-$3.0M↓9%-$2.8M
    Free Cash Flow-----$513.0K-$1.4M↑68%-$4.3M↓10%-$3.9M↓27%-$3.1M↓2%-$3.0M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    NXGL vs Peers — Financial Grading

    Revenue$11.4MBottom 25%
    Net Income$3.0MBottom 25%
    ROE-67.3%Bottom 25%
    D/E0.13Top 25%
    Op. Margin-29.3%Bottom 25%
    Curr. Ratio1.47Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11